Entecavir prevents hep B reactivation when starting chemo
Researchers suggest that patients with chronic hepatitis B virus (HBV) infection who must undergo cancer chemotherapy may avoid reactivation of HBV if they receive prophylaxis with entecavir (Baraclude). If HBV is reactivated because of chemotherapy-related immunosuppression, the patient’s treatment may be complicated by subsequent liver damage, hence the need to keep the virus in check.